FRESENIUS SE+CO. ADR 1/4 (FREA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, FRESENIUS SE+CO. ADR 1/4 (FREA) has a cash flow conversion efficiency ratio of 0.068x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€1.34 Billion ≈ $1.57 Billion USD) by net assets (€19.77 Billion ≈ $23.11 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of FRESENIUS SE+CO. ADR 1/4 to measure how much of total assets are equity-financed.
FRESENIUS SE+CO. ADR 1/4 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how FRESENIUS SE+CO. ADR 1/4's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check FREA cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
FRESENIUS SE+CO. ADR 1/4 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of FRESENIUS SE+CO. ADR 1/4 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chroma ATE Inc
TW:2360
|
0.032x |
|
Amrize Ltd
NYSE:AMRZ
|
0.066x |
|
Tapestry Inc
NYSE:TPR
|
0.385x |
|
China National Nuclear Power
SHG:601985
|
0.057x |
|
QBE Insurance Group Limited
AU:QBE
|
0.210x |
|
Ecopetrol SA ADR
NYSE:EC
|
0.061x |
|
Ares Management LP
NYSE:ARES
|
0.048x |
|
ACS Actividades de Construccion y Servicios SA
MC:ACS
|
0.330x |
Annual Cash Flow Conversion Efficiency for FRESENIUS SE+CO. ADR 1/4 (2021–2025)
The table below shows the annual cash flow conversion efficiency of FRESENIUS SE+CO. ADR 1/4 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see FREA company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €19.77 Billion ≈ $23.11 Billion |
€2.57 Billion ≈ $3.01 Billion |
0.130x | +7.97% |
| 2024-12-31 | €20.29 Billion ≈ $23.72 Billion |
€2.45 Billion ≈ $2.86 Billion |
0.121x | -46.81% |
| 2023-12-31 | €19.65 Billion ≈ $22.97 Billion |
€4.46 Billion ≈ $5.21 Billion |
0.227x | +74.03% |
| 2022-12-31 | €32.22 Billion ≈ $37.67 Billion |
€4.20 Billion ≈ $4.91 Billion |
0.130x | -24.85% |
| 2021-12-31 | €29.29 Billion ≈ $34.24 Billion |
€5.08 Billion ≈ $5.94 Billion |
0.173x | -- |
About FRESENIUS SE+CO. ADR 1/4
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through Fresenius Kabi and Fresenius Helios segment. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machin… Read more